Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5045377 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A: Previously untreated | EXPERIMENTAL | - |
| B: Relapse/Refractory | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO5045377 | DRUG | Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle |
| cytarabine | DRUG | 20 mg/m2 sc, Days 1 to 10 of each 28-day cycle |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Patients with histologically or cytologically documented acute myelogenous leukemia appropriate for cytarabine therapy including: * Arm A: Patients who have not received prior standard induction chemotherapy, considered unsuitable for sta...
RO5045377 is an investigational small molecule being studied for the treatment of acute myelogenous leukemia, a type of cancer that affects the blood and bone marrow. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
RO5045377 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded on the OTC market under the ticker symbol RHHBY.
RO5045377 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. A Phase 1 trial has been completed to evaluate its safety and tolerability in patients with acute myelogenous leukemia.
RO5045377 has been studied in one completed Phase 1 clinical trial, identified as NCT01635296. This trial evaluated the drug in combination with cytarabine in patients with acute myelogenous leukemia. The study enrolled 43 participants across the United States, Canada, France, Italy, and the United Kingdom.
RO5045377 is closely related to RO5045337, which is the compound named in the clinical trial NCT01635296. The trial title refers to RO5045337, while the drug asset is listed as RO5045377, suggesting they may be the same or highly similar investigational agents.